You are viewing the site in preview mode

Skip to main content


  • Poster presentation
  • Open Access

Immune profiling in human breast cancer is predictive of 5- and 10-year survival.

  • 1,
  • 1,
  • 2 and
  • 3
Journal for ImmunoTherapy of Cancer20153 (Suppl 2) :P131

  • Published:


  • Breast Cancer
  • Breast Cancer Patient
  • Breast Carcinoma
  • Human Breast Cancer
  • Receptor Expression


Immunotherapy for breast cancer is now being seriously considered, despite past beliefs that this cancer type was non-immunogenic. Immune profiling has been variably associated with outcome, but standard techniques have greatly limited interpretation. These studies examine immune profiling of breast cancer patients using high-sensitivity methods in relation to clinical outcome.


High-sensitivity detection and analysis methods were used to determine Immune Profiles of female human breast cancer in Tumour Infiltrating Leukocytes (TIL) in longitudinal cohort comparative outcome studies.


Immune profiles showed predominantly CD3, CD4, CD45RO TIL with low/absent IL-2a receptor expression. However, these were significantly correlated to 5- and 10-year survival times.


Immune profiling of the TIL infiltrate in human breast carcinoma using high-sensitivity detection and analysis techniques showed predominance of CD3 cells, being ab-TCR, CD4 T cells of mainly memory phenotype. Importantly, these findings were strongly predictive of 5- and 10-year survival. This indicates the real possibility that TIL infiltration in breast cancer might be open to immunological manipulation therapeutically to improve clinical outcome.

Authors’ Affiliations

Discipline of Surgery, University of Adelaide & Breast, Endocrine & Surgical Oncology Unit, Royal Adelaide Hospital, Australia
Department of Clinical Immunology, Flinders University, Flinders Medical Centre, Adelaide, Australia
Pathology, Flinders University, Flinders Medical Centre, Adelaide, Australia


© Coventry et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.